Onconova Therapeutics Stock Price

0.0104 (1.79%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Onconova Therapeutics Inc ONTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.0056 -0.96% 0.5795 0.5731 0.61 0.5999 0.5851 00:00:06
Bid Price Ask Price Spread Spread % News
0.5801 0.65 0.0699 10.75% 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
4,940 3,543,380 $ 0.5877401 $ 2,082,587 14,625,467 0.1027 - 3.09
Last Trade Time Type Quantity Stock Price Currency
19:30:34 formt 1,000 $ 0.5899 USD

Onconova Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 97.74M 168.67M 167.09M $ 2.18M $ - -1.50 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Onconova Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.560.6390.52120.57594997,891,7680.01953.48%
1 Month0.460.7390.4330.571761314,529,9070.119525.98%
3 Months0.2950.7390.2850.471335110,528,4230.284596.44%
6 Months0.410.7490.2730.459388113,247,7300.169541.34%
1 Year2.883.090.10270.42175649,784,146-2.30-79.88%
3 Years32.2542.450.10271.373,703,276-31.67-98.2%
5 Years41.10122.550.10272.292,296,911-40.52-98.59%

Onconova Therapeutics Description

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks signaling by targeting RAS effeccellular tor pathways.

Your Recent History
Onconova T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.